The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.
KT-US-499-0150
Phase 1 other active
Quick answer
The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma. for Relapsed and/or Refractory B-cell Lymphoma is a Phase 1 program (other) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Relapsed and/or Refractory B-cell Lymphoma
- Phase
- Phase 1
- Modality
- other
- Status
- active